Connect with us

News

Menopause at work: Women face challenges but receive minimal support, study reveals

Women cited working during menopause to be challenging reporting both physical and emotional symptoms

Published

on

Women in the workforce face ‘significant’ challenges due to menopause, but receive minimal support from employers, according to a new survey from Carrot Fertility.

Carrot, a US fertility healthcare and family-forming benefits provider, commissioned the survey ahead of Menopause Awareness Month to understand the effects of menopause on careers, identify the support available and bring more awareness to menopause.

An estimated one billion women worldwide will have experienced menopause by 2025, with millions more going through perimenopause.

Of the 1,000 people experiencing perimenopause or menopause across the US who were surveyed, the vast majority of respondents (79 per cent) describe working during menopause as challenging, more than other common life stages, including starting a new job (75 per cent describe as challenging), starting a family (70 per cent), or getting a promotion (62 per cent).

When asked what age decade is the most challenging for being in the workplace, respondents ranked their 50s as number one, well ahead of second-ranked 20s, according to the study.

Most women reported the need to take time off or faced other serious challenges in the workplace during menopause and perimenopause.

More than half of women (54 per cent) have encountered at least one menopause-driven work challenge, including loss of work time and job security concerns.

Among the nearly 40 per cent of respondents who took time off due to perimenopause or menopause symptoms, 71 per cent lost more than 40 hours of work time, and 30 per cent reported losing more than a month of work time altogether.

Of those who took time off, 59 per cent felt they needed to conceal the reason for the time away.

Other workplace challenges tied to menopause reported by respondents include perceived losses to credibility in the workplace, worries over job loss due to menopause stigma, and lost work friendships.

“We’ve made tremendous progress around the ability to understand and address the fertility challenges impacting younger individuals in their work life, but we are woefully behind when it comes to supporting employees with their fertility healthcare needs as they age,” said Tammy Sun, founder and CEO, Carrot Fertility.

“The findings of this report spotlight the real challenges menopausal women in the workplace struggle with, including lost productivity and concerns over job security. The survey also validates the need for employers and business leaders to provide age-inclusive fertility benefits for employees.”

Most women surveyed were unfamiliar with workplace menopause benefits but highly supportive of the concept, with 82 per cent of respondents see such benefits as valuable.

When asked what type of menopause benefits they deem valuable, a large majority of respondents cited fundamental benefits, such as medical care and support, counselling and therapy, and support groups, as well as other offerings like menopause mentoring and office menopause rooms to manage their symptoms.

While there is high support for employer-provided menopause benefits from people experiencing menopause and perimenopause, such offerings are rare and typically limited to flexible scheduling.

Only eight per cent say their employer has offered significant support for menopause, compared to 59 per cent who report no support at all. Among the 21 per cent whose employers have offered significant or minor support, flexible scheduling is the most common.

The survey showed if employers opted to offer menopause benefits, they would gain significant advantages, including employee retention.

Other advantages for employers who offer benefits are increased job satisfaction and productivity. Among the respondents, 92 per cent have at least one reason for believing menopause benefits should be provided by employers, such as employee retention and workplace fairness.

Few respondents feel prepared for menopause, with 65 per cent describe their experience as difficult and only eight per cent report feeling very prepared and informed for the overall experience of menopause.

Despite the lack of preparedness, women shared that they’ve experienced both physical and emotional symptoms during menopause, including hot flashes, fatigue, night sweats and weight gain.

Mood changes and anxiety were the most commonly reported emotional and mental health symptoms.

The findings of Carrot’s survey highlight the perception that discussing menopause at work is taboo, and the significant impact menopause has on respondents’ personal and professional relationships.

The majority of people surveyed shared that they feel uncomfortable discussing menopause at work, having to seek support from other sources instead.

“The dramatic hormonal changes stemming from menopause can result in symptoms that negatively impact people physically, mentally, and emotionally, in both their personal and professional lives, as confirmed by this survey,” said Dr Asima Ahmad, MD, MPH, co-founder and chief medical officer at Carrot Fertility.

“What’s also crystal clear from this survey is the diversity of support and benefits women in the workplace deem critical to their productivity, ranging from medical care to counselling and emotional support groups. We hope employers are taking note.”

Carrot aims to help employers and health plans provide equal access to fertility care regardless of age, race, income, sex, sexual orientation, gender identity, marital status or location.

Earlier this year, the company developed a new line of clinically-validated, age-inclusive fertility benefits for employees going through every stage of menopause and low testosterone.

Customers have now the option to add support for menopause and low testosterone as part of their fertility benefits package, having access to providers through a specialised network, clinically supervised education and intimate group support.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.